ESR1 and breast carcinoma: In a REMAGUS02 trial, a phase II randomized controlled trial, celecoxib combined with sequential neoadjuvant chemotherapy (NAC) (epirubicin + cyclophosphamide followed by docetaxel) shows poorer event-free survival and distant relapse-free survival and OS than the NAC group, particularly the prostaglandin-endoperoxide synthase 2 (PTGS2; also called COX-2)-low or estrogen receptor-negative group.191 The effects of celecoxib on breast cancer depend on the expression of PTGS2 and estrogen receptor status, as validated in PTGS2-low/high breast cancer cell lines.